AM­AG CMO hits the ex­it just as biotech search­es for new CEO to right a ship rocked by Mak­e­na con­tro­ver­sy

Head­ing in­to 2020, AM­AG Phar­ma­ceu­ti­cals has sketched big plans to sal­vage its wob­bly op­er­a­tions — bat­tling a rev­enue squeeze and a crit­i­cal FDA re­view of its preterm birth drug — un­der a new CEO. To­day, it an­nounced that the chief med­ical of­fi­cer won’t be stay­ing, ei­ther.

Julie Krop, who joined AM­AG in 2015, will de­camp by the end of the month, leav­ing a void in the biotech’s de­vel­op­ment group just as it pledges to per­suade the FDA to keep Mak­e­na on the mar­ket and ad­vance a “po­ten­tial­ly ex­cit­ing pipeline.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.